UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): December 14, 2011
______________________
OPEXA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Texas | 001-33004 | 76-0333165 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 2635 Technology Forest Blvd., The Woodlands, Texas | 77381 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (281) 272-9331 | |
| N/A | |
| (Former name or former address, if changed since last report) | |
______________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 7.01 | Regulation FD Disclosure |
On December 14, 2011, Opexa Therapeutics, Inc. (the “Company”) will deliver a corporate presentation at the Oppenheimer 22nd Annual Healthcare Conference, which will be available via webcast, using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1. The presentation includes an overview of the Company’s ongoing clinical development program for Tovaxin®, the Company’s lead therapy for multiple sclerosis. The attached materials have also been posted to the Investor Relations page of the Company’s website at www.opexatherapeutics.com. The Company does not undertake to update this presentation.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
Exhibit No. | Description |
| 99.1 | Opexa Therapeutics, Inc. Corporate Presentation for Oppenheimer 22nd Annual Healthcare Conference, held on December 14, 2011. |
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities under that Section, nor be deemed to be incorporated by reference into the filings of the registrant under the Securities Act of 1933.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated: December 14, 2011 | OPEXA THERAPEUTICS, INC. | |
| By: | /s/ Neil K. Warma | |
| Neil K. Warma | ||
| President & Chief Executive Officer | ||
3
Exhibit Index
Exhibit No. | Description |
| 99.1 | Opexa Therapeutics, Inc. Corporate Presentation for Oppenheimer 22nd Annual Healthcare Conference, held on December 14, 2011 |